Exelixis (EXEL) investor relations material

Strategic vision and franchise approach

• Focused on building multi-franchise value in oncology, especially GU and GI cancers, by leveraging successful molecules like cabozantinib and advancing next-generation candidates such as zanzalintinib.

• Emphasizes disciplined prioritization, concentrating resources on areas with the highest impact and avoiding overly broad or highly competitive fields like heme-onc.

• Collaboration is central, seeking synergistic partnerships that align on scientific and commercial goals, exemplified by successful joint trials and ongoing alliances.

• Franchise-building is driven by expanding indications, lines of therapy, and modalities, with a measured approach to risk and resource allocation.

• Commercial success is tied to changing standards of care and delivering tangible benefits to patients and stakeholders.

Pipeline development and innovation

• Pipeline includes four clinical-stage molecules, with zanzalintinib prioritized for resource allocation and multiple pivotal trials underway.

• Early-stage assets include ADCs, bispecifics, and inhibitors targeting novel pathways, with a focus on GU/GI and select peripheral indications.

• Success in CRC and RCC is leveraged to expand into new indications, using technologies like Signatera for patient selection and trial design.

• Embraces a data-driven, iterative approach, learning from both successes and failures to refine clinical strategies and maximize probability of technical success.

• Investment in translational technologies and internal capabilities, such as cryo-EM, accelerates discovery and optimization of new candidates.

Commercial and financial execution

• Maintains profitability since 2017, with ongoing share buybacks reflecting confidence in undervalued assets and future growth.

• Integrated organizational structure ensures close collaboration between commercial, discovery, and competitive intelligence teams.

• Financial strength and cash flow enable aggressive pursuit of later-stage assets and strategic investments in pipeline expansion.

• Commercial team competes effectively with larger industry players, leveraging deep market insight to guide development and launch strategies.

• Decision-making is informed by robust modeling and scenario analysis, balancing risk and opportunity in a dynamic market.